Risultati di ricerca
Le rose dei fondatori. Da Batigol a Mr.autogol Negro, da Zio Bergomi a Pietro "il russo" ecco le rose delle antenate di Van Wood e O'Animale.
8 set 2021 · The evaluation of bone marrow morphology by experienced hematopathologists is essential in the diagnosis of acute myeloid leukemia (AML); however, it suffers from a lack of standardization...
- Jan-Niklas Eckardt, Jan Moritz Middeke, Sebastian Riechert, Tim Schmittmann, Anas Shekh Sulaiman, Mi...
- 2021
31 mag 2011 · The AML96 trial included 1,862 patients ≥ 18 years old with primary and secondary or treatment-related AML and refractory anemia with excess of blasts according to the French-American-British (FAB) classification.
- Christoph Röllig, Martin Bornhäuser, Christian Thiede, Franziska Taube, Michael Kramer, Brigitte Moh...
- 2011
12 ago 2010 · We present an analysis of prognostic factors derived from a trial in patients with acute myeloid leukemia older than 60 years. The AML96 trial included 909 patients with a median age of 67 years (range, 61-87 years). Treatment included cytarabine-based induction therapy followed by 1 consolidation. ….
- Christoph Röllig, Christian Thiede, Martin Gramatzki, Walter Aulitzky, Heinrich Bodenstein, Martin B...
- 2010
23 dic 2011 · In a post-hoc analysis of the AML96 study, we investigated whether we could define prognostic and predictive groups with significantly different probabilities of post-remission survival for patients with AML who were treated with high-dose cytarabine, or autologous or allogeneic HSCT in a priority-based and risk-adapted manner.
- Markus Pfirrmann, Gerhard Ehninger, Christian Thiede, Martin Bornhäuser, Michael Kramer, Christoph R...
- 2012
Background: The optimum post-remission treatment (PRT) in acute myeloid leukaemia (AML) is still a matter of debate. Consolidation treatments include chemotherapy with high-dose cytarabine, or allogeneic or autologous haemopoietic stem cell transplantation (HSCT). In a post-hoc analysis of the AML96 trial ( NCT00180115 ), our aim was to ...
10 lug 2011 · We assessed the prognostic value of the new risk classification in a large cohort of patients. Patients and methods: Complete data for classification were available for 1,557 of 1,862 patients treated in the AML96 trial.
